Table 1.
Initial and salvage patient characteristics
| Characteristics | At initial presentation | At salvage | |
|---|---|---|---|
| Age (years) |
Mean 60 |
Mean 65 |
|
| Range 50 - 77 |
Range 60 - 80 |
||
| KPS |
Mean 80 |
Mean 80 |
|
| Range 70 - 90 |
Range 70 - 90 |
||
| PSA ng/ml |
Mean 17.3 |
Mean 5 |
|
| Median 10.7 |
Median 3.7 |
||
| Range 4 - 121 |
Range 1.1 - 30 |
||
| PSA ng/ml |
Patients (%) |
Patients (%) |
|
| < 10 ng/ml |
26 (46%) |
51 (91%) |
|
| 10-20 ng/ml |
18 (32%) |
4 (7%) |
|
| > 20 ng/ml |
12 (22%) |
1 (2%) |
|
| Gleason score |
Patients (%) |
Patients (%) |
|
| ≤ 3 + 3 |
37 (66%) |
9 (16%) |
|
| 3 + 4/4 + 3 |
16 (29%) |
14 (25%) |
|
| ≥ 4 + 4 |
3 (5%) |
8 (14%) |
|
| Unavailable |
|
25 (45%) |
|
| T stage |
Patients (%) |
Patients (%) |
|
| T1c |
23 (41%) |
|
|
| T2 |
26 (46%) |
|
|
| T3 |
7 (13%) |
|
|
| Unknown |
|
|
|
| Recurrent |
|
56 (100%) |
|
| D’Amico risk group |
Patients (%) |
Patients (%) |
|
| Low |
24 (43%) |
|
|
| Intermediate |
16 (28.5%) |
|
|
| High |
16 (28.5%) |
|
|
| Unknown |
|
|
|
| Radiation treatment |
Patients (%) |
Patients (%) |
|
| EBRT |
46 (82.%) |
|
|
| < 72 Gy |
24 (43%) |
|
|
| > 72 Gy |
22 (39%) |
|
|
| LDR-BQT |
10 (18%) |
37 (66%) |
|
| HDR-BQT |
|
19 (34%) |
|
| Time to biochemical relapse |
|
Patients |
Patients |
| (ASTRO/Phoenix definition) |
|
ASTRO |
PHOENIX |
| < 24 months |
|
6 (11%) |
4 (7%) |
| > 24 months |
|
50 (89%) |
52 (93%) |
| Androgen deprivation therapy |
Patients (%) |
Patients (%) |
|
| Yes |
26 (46%) |
15 (27%) |
|
| No |
30 (54%) |
41 (73%) |
|
| Time to nadir post-RT/BQT |
|
|
|
| ≤ 6 months |
15 (26.8%) |
|
|
| 6 – 12 months |
7 (12.5%) |
|
|
| > 12 months |
34 (60.7%) |
|
|
| Nadir PSA post-radiation |
Mean 0.6 ng/ml |
Mean 0,5 ng/ml |
|
| Median 0.5 ng/ml |
Median 0.16 ng/ml |
||
| Range 0.001 – 3 ng/ml | Range 0.001 – 2.9 ng/ml | ||
LDR-BQT = low dose rate brachytherapy; HDR-BQT = high dose rate brachytherapy.